What Success TMS does

Success TMS is a private U.S. therapeutic clinic operator founded in 2017 and headquartered in Boca Raton, Florida, that administers non-medication and medication-assisted treatments for depression, primarily transcranial magnetic stimulation (TMS) and esketamine nasal spray. The company's two core offerings are NeuroStar TMS Therapy, an FDA-cleared, non-invasive magnetic-stimulation protocol targeting brain regions associated with mood regulation, and SPRAVATO (esketamine), an FDA-approved nasal spray from Janssen Pharmaceuticals indicated for treatment-resistant depression and MDD with suicidal ideation. Success TMS does not own the underlying device or pharmaceutical IP; it is an administrator and clinical-services provider running a multi-location U.S. clinic footprint.

The business model is direct-to-consumer healthcare delivered through owned physical clinics, complemented by a healthcare-provider referral channel ('For Providers'). Pricing is not publicly disclosed; reimbursement is driven by insurance billing, with the company accepting most major commercial plans, Medicare, and Medicaid at various locations and handling paperwork, claims filing, processing, and appeals on its own. The primary customer segment is patients with treatment-resistant depression who have not responded adequately to talk therapy or antidepressant medication, with a secondary segment of patients who prefer to avoid systemic drug side effects.

Growth has been physical rather than technological: scaling from a single 2017 founding site to a multi-state footprint supported by 251-500 employees. Marketing is multi-channel — website content, patient testimonials, online PHQ-10 and TMS-eligibility self-assessments, phone consultations, and a provider referral program. The company's competitive positioning rests on the FDA status of its administered modalities, in-house insurance handling, convenience of clinic locations, and specialist brand focus on depression remission. No proprietary technology, AI capabilities, or financial disclosures are present in the available data.

Name

Success TMS

Legal name

Greenbrook TMS NeuroHealth Centers

Website

https://successtms.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

251–500 employees

Short description

Success TMS is a private, multi-location U.S. clinic operator founded in 2017 that administers FDA-cleared NeuroStar TMS therapy and FDA-approved SPRAVATO esketamine to patients with treatment-resistant depression, billing through major insurance plans including Medicare and Medicaid.

Ownership category

akta.pro rank

Product category

Mental Health Services / Depression Treatment

NAICS

Offices of Physicians, Mental Health Specialists (621112), Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

Keywords

• Depression treatment
• Transcranial magnetic stimulation
• TMS therapy
• Esketamine treatment
• Mental health services

Headquarters

HQ city

Boca Raton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure, Technology or R&D

Revenue model

1. Clinical Treatment Services: Revenue generated from providing TMS therapy and esketamine nasal spray treatments to patients. The company handles insurance billing directly, filing and processing claims on behalf of patients. Treatments can be stand-alone or combined with existing medication regimens.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Success TMS is a therapeutic clinic that provides non-medication and medication-based treatments for depression, primarily NeuroStar Transcranial Magnetic Stimulation (TMS) Therapy and SPRAVATO (esketamine) nasal spray treatments. The company targets patients with treatment-resistant depression or those seeking alternatives to traditional antidepressant medications, administering FDA-cleared/approved therapies at multiple US clinic locations while handling all insurance paperwork, claims filing, and appeals on behalf of patients.

Product overview

Greenbrook TMS offers two FDA-cleared/approved depression treatments: NeuroStar TMS Therapy (a non-medication transcranial magnetic stimulation therapy) and SPRAVATO (an FDA-approved esketamine nasal spray). Both treatments are designed for patients struggling with depression who have not found relief through traditional treatments like talk therapy or antidepressant medication.

Differentiator

Problem solved

Functional benefit

Brands

• NeuroStar TMS Therapy: FDA-cleared, non-medication depression treatment using transcranial magnetic stimulation technology.
• SPRAVATO

Products and services

• NeuroStar TMS Therapy FDA-cleared, non-medication transcranial magnetic stimulation therapy for depression that targets brain areas associated with mood regulation using magnetic pulses; intended for adult patients with depression who have not found adequate relief from talk therapy or oral antidepressants, or who want to avoid systemic drug side effects.
• SPRAVATO (esketamine) Nasal Spray Treatment FDA-approved esketamine nasal spray treatment administered in-clinic for adults with treatment-resistant depression or depressive symptoms in adults with MDD with suicidal thoughts or actions; can be used as a stand-alone therapy or in combination with oral antidepressants.

Quantifiable outcome

• Patient testimonials report relief from depression after first treatment session

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core.

• NeuroStar (Neuronetics)coreTechnology or IntegrationGreenbrook uses NeuroStar TMS Therapy, an FDA-cleared transcranial magnetic stimulation system for treating depression. The company operates as a treatment provider utilizing Neuronetics' proprietary TMS technology platform. NeuroStar is the technology provider while Greenbrook operates treatment centers.
• SPRAVATO (Janssen Pharmaceuticals)coreTechnology or IntegrationGreenbrook provides SPRAVATO (esketamine) nasal spray treatments, an FDA-approved medication manufactured by Janssen Pharmaceuticals (a Johnson & Johnson company) for treatment-resistant depression. Greenbrook administers the treatment in its clinic locations.
• Major Insurance CompaniescoreGTM or Marketing PartnerGreenbrook partners with major insurance companies for coverage of TMS and esketamine treatments. The company handles all paperwork, claims filing, processing, and appeals on behalf of patients. Coverage includes Medicare and Medicaid at various locations.

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Acadia Healthcare: Large publicly traded behavioral health services provider operating inpatient psychiatric facilities and outpatient programs. Provides a benchmark for specialty mental health services at scale, though broader in scope than Success TMS.
• Cerebral: Direct-to-consumer mental health platform offering telehealth psychiatry, therapy, and medication management. Competes for the same patient acquisition channels and consumer mental health spend, though its delivery model is digital rather than in-clinic.
• Lyra Health: Enterprise mental health benefits platform connecting employees to therapy, coaching, and medication management. Represents the broader employer-funded mental health category in which Success TMS competes for specialty referrals.
• Universal Health Services: Large diversified hospital and behavioral health operator with significant inpatient psychiatric capacity. Broad incumbent in behavioral health services delivery, much larger and broader in scope than Success TMS.
• Talkspace: Public online therapy platform serving consumers and enterprise clients. Adjacent behavioral health provider that competes for the same self-pay and employer-sponsored mental health patient pool as Success TMS.

Regional players

• Behavioral Health Group: Outpatient behavioral health services provider focused on substance use disorder treatment. Operates in an adjacent behavioral health services niche with comparable multi-site clinic delivery model.

Others

• Neuronetics: Manufacturer of the NeuroStar TMS system used by Success TMS and now operator of Greenbrook clinics. Acts as a technology supplier and vertically integrated competitor shaping the broader TMS clinic economics.

Direct peers

• Greenbrook TMS: Operated a multi-site US TMS clinic network using NeuroStar technology and SPRAVATO before being acquired by Neuronetics. Highly comparable specialty behavioral health clinic operating model targeting treatment-resistant depression.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/successtms

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Success TMS